aTyr Pharma has November 5, 2026 results. aTyr Pharma stock sits below EUR 0.80 high
Published on 10/24/2026 at 18:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date November 5, 2026
- MarketBeat estimates aTyr Pharma will report third-quarter results on November 5, 2026.
- The preview expects USD 2.50 million in third-quarter revenue.
- aTyr Pharma stock stood at EUR 0.07 in Frankfurt on October 23, 2026, while the 52-week high was EUR 0.80.
aTyr Pharma (US0021202025) has an estimated third-quarter reporting date of November 5, 2026, with consensus revenue of USD 2.50 million. MarketBeat also lists expected earnings per share of minus USD 0.11 for the quarter. The Frankfurt quote stood at EUR 0.07 on October 23, 2026.
Analyst targets remain elevated
TradingView reported on October 22, 2026 that the average 12-month target from five analysts rose from USD 2.83 to USD 3.20. The same review listed seven covering analysts, including three Buy ratings, four Holds and no Sells. The target remains a high-risk benchmark because the company is still in clinical development rather than commercial operations.
Price position before the report
The Frankfurt quote page listed a 52-week range of EUR 0.05 to EUR 0.80 as of October 23, 2026. At EUR 0.07, the stock stood 91.00 percent below that high and 40.00 percent above the low. The Nasdaq quote was USD 0.17 at 4:00 p.m. Eastern Time on October 23, 2026, with a market capitalization of USD 16.2 million and volume of 1,293,515 shares.
Clinical pipeline sets the backdrop
aTyr describes itself as a clinical-stage biotechnology company developing therapies for fibrosis and inflammation. Its lead candidate is efzofitimod, which is being studied in pulmonary sarcoidosis and systemic sclerosis-related interstitial lung disease, according to the aTyr Pharma investor site. For the second quarter of 2026, MarketBeat reported adjusted earnings per share of minus USD 0.11, compared with consensus of minus USD 0.1214.
The company reported USD 16.16 million in cash at June 30, 2026, while operating cash flow for the quarter was negative USD 9.35 million. Those figures leave the November report focused on cash use, clinical progress and the timing of future financing needs.
What comes next for investors
The November 5 report is expected before the market opens, followed by a conference call scheduled for November 6, 2026, at 4:00 p.m. Eastern Time. aTyr's investor page identifies Nasdaq as the primary exchange and efzofitimod as the lead development program.
Market context: Market report Nasdaq Composite.
